ANI Pharmaceuticals Reports Third Quarter 2022 Financial Results; Reports Record Net Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- AMD shares fall amid AI chip sector selloff
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- JetBlue shares fall amid American results, fuel cost concerns
ANI Pharma (ANIP) Tops Q3 EPS by 11c, Offers Guidance
November 9, 2022 7:28 AM ESTANI Pharma (NASDAQ: ANIP) reported Q3 EPS of $0.64, $0.11 better than the analyst estimate of $0.53. Revenue for the quarter came in at $83.8 million versus the consensus estimate of $77.2 million.
GUIDANCE:
ANI Pharma sees FY2022 EPS of $1.34-$1.62, versus the consensus... More



